European Equities Traded in the US as American Depositary Receipts Tread Water in Thursday Trading

MT Newswires Live
Yesterday

European equities traded in the US as American depositary receipts were treading water late Thursday morning, edging 0.1% higher to 1,396.7 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by medical device maker EDAP TMS (EDAP) and pharmaceutical company Novo Nordisk (NVO), which rose 4.7% and 3.3% respectively. They were followed by pharmaceutical company Ascendis Pharma (ASND) and telecommunications operator Telefonica (TEF), which were up 1.7% and 1.5% respectively.

The decliners from continental Europe were led by semiconductor company Sequans Communications (SQNS) and software firm SAP (SAP), which fell 2.7% and 2.3% respectively. They were followed by biotechnology companies argenx (ARGX) and Evaxion Biotech (EVAX), which dropped 2.1% and 0.9% respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical companies Akari Therapeutics (AKTX) and telecommunications operator Vodafone Group (VOD), which increased 5.2% and 3% respectively. They were followed by pharmaceutical companies Amarin (AMRN) and AstraZeneca (AZN), which advanced 2.8% and 1.4% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical company NuCana (NCNA) and Barclays (BCS), which lost 2.7% and 2.4% respectively. They were followed by biopharmaceutical companies TC Biopharm (TCBP) and Silence Therapeutics (SLN), which were down 1.8% and 1.2% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10